NGeneBio Co., Ltd.

A354200

KR7354200008

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-13 EDT			5-day change	1st Jan Change
3,795 ^KRW	+0.66%		-4.29%	-31.74%

04-22	NGENEBIO USA Holdings, INC. announced that it expects to receive KRW 3.7395 billion in funding from NGeneBio Co., Ltd.	CI
04-15	J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. from Gencurix Inc. for KRW 3 billion.	CI

NGeneBio Co., Ltd.(KOSDAQ:A354200) added to S&P Global BMI Index

June 21, 2021 at 12:00 am

Latest news about NGeneBio Co., Ltd.

NGENEBIO USA Holdings, INC. announced that it expects to receive KRW 3.7395 billion in funding from NGeneBio Co., Ltd.	04-21	CI
J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. from Gencurix Inc. for KRW 3 billion.	04-14	CI
J&L Agent Co., Ltd. and other buyer agreed to acquire 4.97% stake in NGeneBio Co., Ltd. from Gencurix Inc. for KRW 3.2 billion.	04-02	CI
NGENEBIO USA HOLDINGS, INC., announced that it has received KRW 4.0161 billion in funding from NGeneBio Co., Ltd.	03-20	CI
South Korea's NGeneBio Joins CancerX Partnership	23-10-12	MT
MGI Tech Co., Ltd. Partners with NGeneBio Co., Ltd. to Advance Precision Medicine	23-08-22	CI
NGeneBio Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
NGeneBio Co., Ltd.(KOSDAQ:A354200) dropped from S&P Global BMI Index	22-09-19	CI
NGeneBio Co., Ltd. announced that it has received KRW 20 billion in funding from SK Securities Co., Ltd., Investment Arm, Shinhan Investment Corp., Investment Arm, and other investors.	22-08-31	CI
NGeneBio Co., Ltd. announced that it expects to receive KRW 20 billion in funding from SK Securities Co., Ltd., Investment Arm, Shinhan Investment Corp., Investment Arm, and other investors.	22-08-29	CI
NGeneBio Co., Ltd.(KOSDAQ:A354200) added to S&P Global BMI Index	21-06-21	CI
NGeneBio Co., Ltd. has completed an IPO in the amount of KRW 34.216 billion.	20-12-04	CI
NGeneBio Co., Ltd. has filed an IPO.	20-07-31	CI

NGeneBio Co Ltd is a Korea-based company engaged in the manufacture and sale of precision diagnostic products. The Company's main products include BRCAaccuTest products used for hereditary breast and ovarian cancer testing, HEMEaccuTest products that tests the causative genes related to blood cancer such as leukemia, lymphoma, and bone marrow cancer, SOLIDaccuTest products that test the causative genes of solid cancer tissues such as lung cancer, colon cancer and stomach cancer. In addition, the Company manufactures and sells products of HLAaccuTest products that tests tissue-specific antigens used for bone marrow transplantation, ONCOaccuPanel products for precise diagnosis of large-capacity solid cancer, HEREDaccuTest products for precise diagnosis for rare diseases. The Company also provides services such as genetic testing direct to customer(DTC) and personalized healthcare.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
NGENEBIO CO., LTD.	-31.74%	36.15M
BIOMÉRIEUX	-4.08%	12.32B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-4.76%	8.1B
DIASORIN S.P.A.	+9.50%	5.87B
LANTHEUS HOLDINGS, INC.	+28.39%	5.52B
AUTOBIO DIAGNOSTICS CO., LTD.	-6.28%	4.29B
10X GENOMICS, INC.	-52.84%	3.16B
ANDON HEALTH CO., LTD.	+12.93%	2.72B
VITROLIFE AB	-3.08%	2.37B
MYRIAD GENETICS, INC.	+28.84%	2.23B

Diagnostic & Testing Substances

NGeneBio Co., Ltd.

Equities

A354200

KR7354200008

Medical Equipment, Supplies & Distribution

NGeneBio Co., Ltd.(KOSDAQ:A354200) added to S&P Global BMI Index

Latest news about NGeneBio Co., Ltd.

Chart NGeneBio Co., Ltd.

Company Profile

Income Statement Evolution

Sector Diagnostic & Testing Substances